Frontage Holdings Corp represents values of innovation, excellence, and client-centricity. With a strong corporate philosophy, the company strives for continuous growth by providing exceptional services and solutions in the healthcare and pharmaceutical industries. Frontage Holdings Corp is committed to delivering high-quality results and meeting clients' needs through cutting-edge technology, extensive expertise, and a dedicated team. As a trusted partner, Frontage Holdings Corp consistently aims to exceed expectations, foster long-term relationships, and contribute to the advancement of global healthcare.

Frontage Holdings Corp is primarily present in China and the United States.

Frontage Holdings Corp has achieved several significant milestones in its history. The company successfully went public in [year], marking a major achievement in its growth trajectory. Additionally, Frontage Holdings Corp expanded its operations and now operates in [number] countries, further enhancing its global presence. The company has also made notable advancements in [specific field/industry], consolidating its position as a leader in this area. Frontage Holdings Corp has continually demonstrated its commitment to innovation, consistently releasing cutting-edge products and services. These accomplishments have solidified the company's reputation as a top player in the market and have contributed to its continued success.

Frontage Holdings Corp is a leading provider of pharmaceutical R&D services in China. Established in 2014, it has rapidly grown to become a trusted partner for global pharmaceutical and biotech companies. Frontage offers a comprehensive range of services, including preclinical and clinical research, bioanalysis, data management, and regulatory support. With state-of-the-art facilities and a team of experienced scientists, Frontage delivers high-quality solutions to accelerate drug development. The company's commitment to innovative research and customer satisfaction has earned it a strong reputation in the industry. Frontage Holdings Corp continues to drive advancements in pharmaceutical sciences, contributing to improving global healthcare outcomes.

The main competitors of Frontage Holdings Corp in the market include Covance Inc., Charles River Laboratories International, Inc., and WuXi AppTec Holdings Inc.

Frontage Holdings Corp is primarily active in the Contract Research Organization (CRO) industry. As a leading provider of integrated pharmaceutical R&D services, Frontage Holdings Corp offers a comprehensive range of solutions to support drug discovery and development. With a focus on bioanalytical, preclinical, and clinical research services, the company plays a vital role in advancing healthcare and pharmaceutical innovations. Through its expertise and extensive network, Frontage Holdings Corp serves clients across various sectors, including pharmaceuticals, biotechnology, and medical device companies.

Frontage Holdings Corp is a publicly traded company renowned for its business focus on providing integrated drug development solutions to pharmaceutical, biotechnology, and medical device companies. As a leading service provider, Frontage offers a comprehensive range of preclinical and clinical research services, including bioanalytical testing, drug metabolism analysis, and early-stage clinical trials. With a dedication to quality and scientific expertise, Frontage endeavors to accelerate the drug development process, enabling clients to bring innovative therapies to market more efficiently. With its robust service offerings and commitment to industry excellence, Frontage Holdings Corp is at the forefront of facilitating advancements in healthcare and the pharmaceutical industry.

Frontage Holdings KGV ir 13,06.

Frontage Holdings KUV ir 0,98.

AlleAktien kvalitātes vērtējums Frontage Holdings ir 3/10.

gaidāmā Frontage Holdings apgrozījums ir 275,97 milj. USD.

gaidāmā Frontage Holdings peļņa ir 20,76 milj. USD.

Frontage Holdings Corp is a leading provider of CRO services (Contract Research Organization) specializing in pharmaceutical and medical research, development, and manufacturing in Asia. The company offers a wide range of services including clinical research, preclinical development, pharmaceutical development, and analytics. The Clinical Research Services (CRS) division of Frontage offers a broad range of clinical research services including study conduct, data management, statistical data analysis, and clinical study reporting. Frontage CRS supports companies in drug development from concept to market launch. The Preclinical Development Services (PDS) division focuses on animal studies and preclinical studies. PDS conducts studies to evaluate the safety and efficacy of new drugs, including studying the pharmacokinetic properties of a substance. The Pharmaceutical Development Services (PDS) division of Frontage specializes in drug development, utilizing precision medicine and computer-assisted processes. Frontage offers a wide range of services including drug development and formulation, manufacturing and packaging, as well as quality and compliance. Frontage also offers Analytical Services to help companies monitor and evaluate drugs. The company provides services that assess the purity, efficacy, and safety of products, while also considering quality assurance and compliance. Frontage is a one-stop solution provider for pharmaceutical companies, offering support in product development, registration support, market launch, and commercial support. The goal of Frontage is to provide services that accelerate drug development and improve global health.

Frontage Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Frontage Holdings vai uzņēmums nedod dividendes.

Frontage Holdings ISIN ir KYG3679P1019.

Frontage Holdings simbols ir 1521.HK.

Pēdējo 12 mēnešu laikā Frontage Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Frontage Holdings plāno maksāt dividendes 0 USD apmērā.

Frontage Holdings pašreizējā dividendu rentabilitāte ir .

Frontage Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Frontage Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Frontage Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Frontage Holdings apmērā 0 USD, kas tika izmaksāta 16.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.11.2024..

Pēdējās dividendes izmaksa notika 16.11.2024..

Gadā 2023, Frontage Holdings izmaksāja 0 USD dividendes.

Frontage Holdings dividendes tiek izmaksātas USD.